Barclays notes that SpringWorks Therapeutics’ (SWTX) Ogsiveo was included on today’s Committee for Medicinal Products for Human Use agenda, which could lead to a positive opinion for Ogsiveo and enable EU approval. Such an event “could be an important de-risker for potential acquisition of the company” by Merck KGaA (MKGAY), argues the analyst, who has an Overweight rating and $63 price target on SpringWorks shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX: